Maybe Logo Early Access

Tools / Inside Trading Tracker

Inside Trading Tracker

Track insider trading activity at publicly traded companies to understand how executives are trading their shares.

    Zynex Inc (ZYXI) Insider Trading Activity

    Healthcare • Medical Distribution • 1,100 employees

    Zynex, Inc., together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device. It also supplies private labeled products, including electrodes for the delivery of electrical current to the body, and batteries for use in electrotherapy products. In addition, the company distributes Comfortrac/Saunders for cervical traction, JetStream for hot/cold therapy, LSO Back Braces for lumbar support, and braces for rehabilitation support. Further, it offers Zynex Fluid Monitoring System (CM-1500); Zynex Wireless Fluid Monitoring System (CM-1600), a noninvasive monitoring device designed to measure relative changes in fluid volume in adult patients; NiCO CO-Oximeter, a laser-based noninvasive co-oximeter; and HemeOx tHb Oximeter, a laser-based total hemoglobin pulse oximeter. The company provides its products for use in pain management and control; stroke and spinal cord injury rehabilitation; hemodynamic monitoring and intravascular volume monitoring; and pulse oximetry monitoring. It sells its products through direct sales force primarily in the United States. Zynex, Inc. was founded in 1996 and is headquartered in Englewood, Colorado.

    Total Value

    -$771,895.41

    Total Shares

    -49,687

    Average Trade Value

    -$24,121.73

    Most Active Insider

    Moorhead Daniel J

    Total Activity: $370,462

    Largest Single Transaction

    $134,504

    by Lucsok Anna on Aug 6, 2024

    30-Day Activity

    3 Transactions

    Volume: 9,879 shares
    Value: $119,539

    Name
    Position
    Date
    Shares
    Value
    Holdings
    Type
    Chief Financial Officer
    Dec 5, 2024 4,879 $38,739 35,561 (-13.7%) Payment of Exercise Price
    Chief Financial Officer
    Dec 5, 2024 5,000 $0 66,557 (+7.5%) Grant
    Chief Financial Officer
    Dec 2, 2024 10,000 $80,800 35,190 (-28.4%) Sale
    President, CEO and Chairman
    Nov 14, 2024 2,000 $16,180 14,603,662 (-0.0%) Sale
    President, CEO and Chairman
    Nov 13, 2024 2,000 $16,740 14,605,662 (-0.0%) Sale
    President, CEO and Chairman
    Nov 12, 2024 2,000 $18,480 14,607,662 (-0.0%) Sale
    President, CEO and Chairman
    Nov 11, 2024 2,000 $18,180 14,609,662 (-0.0%) Sale
    President, CEO and Chairman
    Nov 8, 2024 2,000 $17,540 14,611,662 (-0.0%) Sale
    President, CEO and Chairman
    Nov 7, 2024 2,000 $18,340 14,613,662 (-0.0%) Sale
    President, CEO and Chairman
    Nov 6, 2024 2,000 $17,640 14,615,662 (-0.0%) Sale
    President, CEO and Chairman
    Nov 5, 2024 2,000 $16,100 14,617,662 (-0.0%) Sale
    President, CEO and Chairman
    Nov 4, 2024 2,000 $17,340 14,619,350 (-0.0%) Sale
    President, CEO and Chairman
    Nov 1, 2024 2,000 $17,260 14,621,350 (-0.0%) Sale
    Chief Financial Officer
    Nov 1, 2024 10,000 $85,900 44,878 (-22.3%) Sale
    President, CEO and Chairman
    Oct 31, 2024 2,000 $17,640 14,623,350 (-0.0%) Sale
    President, CEO and Chairman
    Oct 30, 2024 2,000 $17,840 14,625,350 (-0.0%) Sale
    Chief Financial Officer
    Oct 29, 2024 6,912 $0 74,696 (+9.3%) Grant
    Chief Operating Officer
    Oct 29, 2024 2,764 $0 74,101 (+3.7%) Grant
    President, CEO and Chairman
    Oct 29, 2024 6,912 $0 21,196 (+32.6%) Grant
    Chief Operating Officer
    Oct 27, 2024 5,000 $0 72,014 (+6.9%) Grant
    Chief Operating Officer
    Oct 27, 2024 2,323 $21,186 22,036 (-10.5%) Payment of Exercise Price
    Chief Financial Officer
    Sep 5, 2024 5,000 $0 71,363 (+7.0%) Grant
    Chief Financial Officer
    Sep 5, 2024 5,250 $41,423 50,634 (-10.4%) Payment of Exercise Price
    Chief Operating Officer
    Aug 7, 2024 8,083 $64,906 16,980 (-47.6%) Sale
    Chief Operating Officer
    Aug 6, 2024 16,792 $134,504 25,063 (-67.0%) Sale
    Chief Operating Officer
    Jul 30, 2024 1,104 $0 74,918 (+1.5%) Grant
    Chief Financial Officer
    Jul 30, 2024 2,760 $0 75,676 (+3.6%) Grant
    President, CEO and Chairman
    Jul 30, 2024 2,760 $0 19,176 (+14.4%) Grant
    Chief Financial Officer
    Jul 30, 2024 15,000 $123,600 46,571 (-32.2%) Sale
    Jul 29, 2024 7,000 $58,233 72,000 (+9.7%) Purchase
    Chief Operating Officer
    Jul 29, 2024 3,572 $29,790 41,201 (-8.7%) Payment of Exercise Price
    Chief Operating Officer
    Jul 27, 2024 5,000 $0 74,620 (+6.7%) Grant